Margins beat expectations despite weak SDC execution and nearly flat sales

The quarter was roughly in line on adjusted earnings, not a clean beat. Adjusted operating income per diluted share was $2.61 versus a published consensus of approximately $2.63, a narrow shortfall; excluding the $382,000 legal settlement, it was $2.68, modestly above expectations. Revenue rose only 1.0% to $60.1 million, while core organic growth was just 0.4% (Financial Highlights).

Profitability was the clear upside surprise. AOI excluding unusual items increased 19.5% and reached 25.6% of revenue, up from 21.7% a year earlier, despite additional investment in SDC (Non-GAAP reconciliation; Management commentary). Gross-margin improvement in BPD, Calibration Solutions, and Clinical Genomics offset weaker performance in the largest division.

The revenue mix still exposes an execution problem. SDC, representing 41% of revenue, declined 3.6% organically because fulfillment and delivery issues delayed customer shipments, and its gross-profit percentage fell 150 basis points (Segment results — Sterilization and Disinfection Control). Growth in BPD and Calibration Solutions—5.0% and 7.6%, respectively—was enough to stabilize total sales but not to produce broad-based acceleration (Segment results — BPD; Segment results — Calibration Solutions).

The balance sheet improved, but the outlook remains deliberately incomplete. Mesa repaid $8.656 million of debt and reduced its total net leverage ratio to 1.85, below its stated 2.0 target (Management commentary). However, management deferred full-year guidance until November, so the filing improves confidence in margins and deleveraging without materially changing the revenue outlook. Reported net income fell 40.3% to $2.830 million, but that comparison was distorted by a roughly $6.15 million foreign-currency gain in the prior-year quarter (Income Statement; Management commentary).